Rh antibodies have been associated with which of the following clinical conditions?

Skip Nav Destination

REVIEW ARTICLE| January 15, 2000

Neil D. Avent,

1From the Department of Biological and Biomedical Sciences, University of the West of England, Bristol, England, and the New York Blood Center, New York, NY.

Search for other works by this author on:

Marion E. Reid

1From the Department of Biological and Biomedical Sciences, University of the West of England, Bristol, England, and the New York Blood Center, New York, NY.

Search for other works by this author on:

Blood (2000) 95 (2): 375–387.

Split-Screen
Tools Icon Tools
Search Site
PDF

The Rh blood group system is one of the most polymorphic and immunogenic systems known in humans. In the past decade, intense investigation has yielded considerable knowledge of the molecular background of this system. The genes encoding 2 distinct Rh proteins that carry C or c together with either E or e antigens, and the D antigen, have been cloned, and the molecular bases of many of the antigens and of the phenotypes have been determined. A related protein, the Rh glycoprotein is essential for assembly of the Rh protein complex in the erythrocyte membrane and for expression of Rh antigens. The purpose of this review is to provide an overview of several aspects of the Rh blood group system, including the confusing terminology, progress in molecular understanding, and how this developing knowledge can be used in the clinical setting. Extensive documentation is provided to enable the interested reader to obtain further information.

The Rh blood group system was first described 60 years ago. A woman had a severe transfusion reaction when she was transfused with blood from her husband following delivery of a stillborn child with erythroblastosis fetalis. Her serum agglutinated red blood cells (RBCs) from her husband and from 80% of Caucasian ABO-compatible donors.1 The following year, Landsteiner and Wiener2 found that sera from rabbits (and later guinea pigs) immunized with RBCs from Macaca mulatta (Macacus rhesus in the original paper) agglutinated 85% of human RBC samples. Initially, it was thought that the animal and human antibodies identified a common factor, Rh, on the surface of rhesus and human RBCs. It was soon realized that this was not the case.3 Therefore, the original terms (Rh factor and anti-Rh) coined by Landsteiner and Wiener, although being misnomers, have continued in common usage. The heteroantibody was renamed anti-LW (after Landsteiner and Wiener), and the human alloantibody was renamed anti-D.4

The Rh blood group system is the most polymorphic of the human blood groups, consisting of at least 45 independent antigens and, next to ABO, is the most clinically significant in transfusion medicine. The ability to clone complementary DNA (cDNA) and sequence genes encoding the Rh proteins has led to an understanding of the molecular bases associated with some of the Rh antigens. Serologic detection of polymorphic blood group antigens and of phenotypes provides a valuable source of appropriate blood samples for study at the molecular level. This review summarizes our present understanding of the complexities of Rh blood group expression and how this knowledge impacts on clinical situations that arise through Rh blood group incompatibility.

Terminology

Several nomenclatures have been used to describe antigens, proteins, and genes in the Rh system. Throughout this review, we will use traditional terminology recommended by the International Society of Blood Transfusion (ISBT) committee for terminology of blood group antigens.5 The numeric portion of the ISBT terminology for Rh antigens is based on the nomenclature described by Rosenfield et al.6-9 RH30 and RH50 have been used to describe genes encoding Rh proteins (Rh30) and Rh glycoprotein (Rh50), respectively, where the numbers relate to the apparent molecular mass of the proteins on a SDS-polyacrylamide gel. Because Rh30 and Rh50 also relate to Goa and FPTT antigens, respectively, we will useRH as a generic term for genes encoding either the RhD protein or the RhCcEe (also known as RhCE) protein and use RHAG for the gene encoding the Rh-associated glycoprotein (RhAG). The common Rh antigens: D, C or c, and E or e, were originally written in alphabetical order (CDE) but later, when it was recognized that C and E antigens are inherited en bloc, the order was changed to DCE. Although d antigen, which was thought to be antithetical to D, does not exist, the letter “d” is used to indicate the D-negative phenotype. The most frequently occurring forms of RHCE and RHD encode 8 haplotypes: Dce, dce, DCe, dCe, DcE, dcE, DCE, and dCE, known in short, respectively, as R0, r, R1, r′, R2, r″, Rz, and ry. The uppercase “R” is used when the D antigen is expressed, lowercase “r” when it is not. This notation has practical value in transfusion medicine as a means to communicate the Rh phenotype of a patient or donor. Rare deletion phentoypes use dashes in the notation to indicate a lack of antithetical antigens; eg, Dc−. RBCs lack E and e antigens, and D−− RBCs lack C, c, E, and e antigens. RBCs with the Rhnullphenotype do not express any of the Rh antigens.

The Rh complex

Biochemical studies, protein purification, and amino acid sequencing of Rh and RhAG are beyond the scope of this article but have been reviewed elsewhere.10-16

The Rh proteins carry Rh antigens but are only expressed on the erythrocyte surface if RhAG is also present. The amino acid sequence homology (approximately 40%) of the Rh and RhAG proteins indicates an ancestral relationship, and collectively they are referred to as the “Rh protein family.” Hydrophobicity profiles, immunochemical analyses, and data obtained through site-directed mutagenesis imply that Rh and RhAG proteins have 12 transmembrane spans with both the N-terminus and C-terminus oriented to the cytoplasm (Figure1).17-24

Fig. 1.

Model of topology for RhAG, RhCE, and RhD.

RhAG (Mr 50 000) consists of 409 amino acids and is encoded by RHAG on chromosome 6p11-p21.1. RhCE and RhD (Mr 30 000) are predicted to have a similar topology and are encoded by RHCE and RHD, which are adjacent on chromosome 1p34-p36. The domain of the RhD protein encoded by each exon is depicted by numbered boxes, which represent the start and finish of each exon. Of the D-specific amino acids, 8 are on the exofacial surface (yellow ovals), and 24 are predicted to reside in the transmembrane and cytoplasmic domains (black ovals). Red ovals represent amino acids that are critical for C/c (Ser103Pro) and E/e (Pro226Ala) antigens; purple ovals represent Ser103 and Ala226 on RhD. The zigzag lines represent the Cys-Leu-Pro motifs that are probably involved in the palmitoylation sites. The N-glycan on the first loop of RhAG is indicated by the branched structure of red circles.

Fig. 1.

Model of topology for RhAG, RhCE, and RhD.

Close modal

“Rh accessory proteins” is a collective term for other glycoproteins that are associated with the Rh protein family as defined by their absence or deficiency from Rhnull RBCs (see below and Table 1).25 Together, the association of the Rh protein family and the Rh accessory proteins is called the “Rh complex.”

Table 1.

Proteins in the Rh Complex in Normal RBC Membranes That May Be Absent or Reduced in Rhnull RBC Membranes

Protein	Antigens	Gene Location	Mr	Accession Numbers for cDNAs
Rh protein family
RhD	D	1p36.13-p34.3180	30-32 kd	X63094, X63097,U66341
RhCcEe	Ce, CE, ce, cE	1p36.13-p34.3180	32-34 kd	X54534, M34015, U66340
RhAG	Carries MB2D10 epitope58	6p21.1-p1117,75,174	45-100 kd	X64594
Rh accessory proteins
LW	LW	19p13.3181	37-47 kd	L27670, L27671
IAP	None known	3q1355	47-52 kd	Z25521
GPB	‘N,’ S, s, U	4q28-q31	20-25 kd	J02982
Band 3	Diego	17q12-q21182	90-100 kd	X77738,M27819

Protein	Antigens	Gene Location	Mr	Accession Numbers for cDNAs
Rh protein family
RhD	D	1p36.13-p34.3180	30-32 kd	X63094, X63097,U66341
RhCcEe	Ce, CE, ce, cE	1p36.13-p34.3180	32-34 kd	X54534, M34015, U66340
RhAG	Carries MB2D10 epitope58	6p21.1-p1117,75,174	45-100 kd	X64594
Rh accessory proteins
LW	LW	19p13.3181	37-47 kd	L27670, L27671
IAP	None known	3q1355	47-52 kd	Z25521
GPB	‘N,’ S, s, U	4q28-q31	20-25 kd	J02982
Band 3	Diego	17q12-q21182	90-100 kd	X77738,M27819

Rh protein family

The complex of the Rh protein family is estimated by density ultracentrifugation to be 170 000 daltons26 and to consist of a tetramer with 2 RhAG molecules and 2 RhCcEe or RhD protein molecules stabilized by both N-terminal and C-terminal domain associations.18,19,26,27 The mode of association of this core complex with Rh-accessory proteins, some of which interact directly with the membrane skeleton, remains undefined.

RhD and RhCcEe proteins.

The RhD protein expresses the D antigen, while the RhCcEe protein carries either C or c antigens (involving the second extracellular loop) together with E or e antigens (involving the fourth extracellular loop) on the same protein.19,28-30 Characteristics of the RhD protein (synonyms: Rh30, Rh30B, Rh30D, D30, Rh30 polypeptide [30 kd], RhXIII, Rh23) and of the RhCcEe protein (synonyms: Rh30, Rh30A, Rh30C [RhCE], Rh30 polypeptide [32 kd], RhIXb cDNA, [RhcE], Rh21 cDNA [RhcE], R6A32, Rhce, RhCe, RhcE, RhCE, CcEe) are summarized in Table 1 and depicted in Figure 1. Analysis of the primary amino acid sequences (inferred from cDNAs) shows that the first 41 N-terminal amino acids of RhD and RhCE/e are identical.20,31-33 and that RhD differs from the common forms of RhCE by only 30 to 35 amino acids along the entire protein.20,28,31-33,35,36 Despite the high degree of homology, the various RhCcEe proteins do not express any D epitopes, and RhD protein does not express C or e antigens.

The Rh proteins are thought to interact with the membrane bilayer by palmitoylation,26,37 where acylated palmitic acid residues are attached to cysteine side chains. These cysteine residues are predicted to be at the boundary of the cytosol and lipid bilayer (Figure 1). Cys-Leu-Pro motifs, flanked by charged amino acids (2 are on RhD and 3 are on RhCcEe) are likely candidates although 2 other cysteine residues (315 and 316) may be alternative sites.20,26 This interaction may explain why alteration of membrane cholesterol concentration affects the accessibility of the D antigen.38 The ability to label Rh proteins with3H-palmitate26,37 indicates that a reversible coenzyme A and adenosine triphosphate (ATP)-dependent acylation-deacylation cycle occurs in mature RBC membranes, which is of unknown significance.

Rh-associated glycoprotein.

The characteristics of RhAG (synonyms: Rh50, Rh glycoprotein Rh50A, D50, MB-2D10 protein, R6A45, GP50, GP50A) are summarized in Table 1 and depicted in Figure 1. One of the 2 potential N-glycan sites is glycosylated. A third site is predicted to be cytoplasmic and, therefore, not accessible for glycosylation.17,39 The N-glycan carries ABH antigens,12 but RhAG is not known to possess a protein-based blood group polymorphism. Based on the predicted amino acid sequence, RhAG shares 39.2% and 38.5% amino acid sequence identity with, respectively, the Rhce and RhD proteins.17,20,31-33

Expression of Rh proteins and RhAG during erythropoiesis.

Rh antigens appear early during erythropoietic differentiation. Anti-D binds to approximately 3% of BFU-E (burst-forming unit, erythroid), 68% of CFU-E (colony-forming unit, erythrocyte), and to all of the more mature erythroid cells. However, the binding of anti-D to proerythroblasts, basophilic erythroblasts, polychromatophilic erythroblasts, and normoblasts was, respectively, 25%, 50%, 66%, and 75% compared with mature RBCs.33 RhAG protein is detectable on CD34 progenitors isolated from cord blood, after culture for 3 to 5 days, while RhCcEe appears after 5 to 7 days, and RhD appears after 9 to 11 days of culture.40 In the fetus, Rh antigens are expressed on RBCs from the 6-week conceptus.41

Possible function of Rh protein family.

The function of the Rh complex remains unclear. Rh proteins have approximately 20% homology to the methylamine permease (Mep) transporters and ammonium transporters (Amt) in yeast, bacteria, and simple plants.42 This family of transporters are uniporters that have evolved to concentrate ammonium salts from the surrounding environment. Higher animals use more complex nitrogen sources, and they eliminate toxic ammonium via the urea cycle and transport it in the form of glutamine and alanine. The role of the Rh complex as a dedicated ammonium transporter is unlikely, but the complex could cotransport ammonium with other cations; however, further study is needed. Matassi et al43 report that RHAG shares greatest homology to MEP2, which behaves as an ammonium sensor and transporter in yeast.44 Furthermore, the presence of RhAG homologs in Caenorhabditis elegans and Geodia cydonium infers they have roles that are not confined to RBCs.

Rh accessory proteins

The blood group antigens associated with the Rh family of proteins, the gene location, their molecular mass, number of copies per RBC, and selected accession numbers are summarized in Table1.

LW glycoprotein.

The LW glycoprotein (synonym: ICAM-4) is a single pass (type I) membrane protein with homology to intercellular adhesion molecules (ICAMs), which are ligands for β2 integrins. LW has been reported to be a ligand for the integrin LFA-1 (synonyms: αLβ2, CD11a/CD18).45

While the LW glycoprotein is absent from RBCs of LW(a−b−) and Rhnull individuals, expression of Rh antigens is normal on LW(a−b−) RBCs. LW antigens are more abundant on D-positive RBCs than on D-negative RBCs from adults, which led to the initial interpretation that anti-D and anti-LW were the same.46,47 It is possible that the LW glycoprotein interacts preferentially with RhD as compared with RhCcEe; however, the nature of such an interaction awaits definition. Interestingly, LW antigens are expressed equally well on D-positive and D-negative RBCs from fetuses and newborns and more strongly than on RBCs from adults.48,49

Integrin-associated protein.

Isoform 2 of integrin-associated protein (IAP; synonyms: CD47, BRIC 125 glycoprotein, AgOAB, 1D8) is present in the RBC membrane, where it is predicted to pass through the RBC membrane 5 times and have 6 potential N-glycan motifs.50,51 IAP carries ABH antigens but no known protein-based blood group antigen. IAP occurs as different isoforms in various tissues where it binds to β3 integrins.50,52 The IAP isoform in RBCs does not bind integrins but does bind thrombospondin53 and may be involved in calcium transport, possibly as a gated channel.54 While the amount of IAP is reduced in RBC membranes from Rhnull and D−− people, it is present in normal levels in lymphoblastoid cell lines from these people.55-57

Glycophorin B.

Glycophorin B (GPB; synonyms: Ss sialoglycoprotein [SGP], δ-SGP, PAS-3) is a type I membrane glycoprotein that has several O-glycans but no N-glycan. The Rh complex appears to aid, but is not essential for, the correct insertion of GPB in RBC membranes. In S−s−U− RBCs that lack GPB, the Rh proteins are apparently normal, but RhAG has increased glycosylation, suggesting a slower migration through the endoplasmic reticulum and Golgi apparatus.39 An interaction of GPB and RhAG may be required for full expression of the U antigen58,59 and, to a lesser extent, S and s antigens (Table 2). Further, the known ability of GPB to form heterodimers with glycophorin A (GPA) may bridge the Rh complex with the band 3/GPA complex, forming a large unit in the RBC membrane.

Table 2.

Comparison of amorph Rhnull, regulator Rhnull, and Rhmod RBCs

Phenotype	Rh Proteins/Antigens	RhAG	LW	IAP	GPB Protein/Antigens	Obligate Heterozygotes	Altered Gene
Rhnull-amorph	Absent	Reduced (20%)	Absent	Reduced by 90%	Reduced by 50%	Express one Rh haplotype*	RHCE (RHDdeleted)
					S/s Normal
					U Weak
Rhnull-regulator	Absent	Absent	Absent	Reduced	Reduced by 70%183	Express both Rh haplotypes	RHAG
					S/s weak
					U Absent
Rhmod	Reduced (variable)	Absent or reduced (variable)	Absent or reduced	Reduced (variable)	Reduced (variable)	Express both Rh haplotypes	RHAG
					S/s Normal
					U Normal/Weak

Phenotype	Rh Proteins/Antigens	RhAG	LW	IAP	GPB Protein/Antigens	Obligate Heterozygotes	Altered Gene
Rhnull-amorph	Absent	Reduced (20%)	Absent	Reduced by 90%	Reduced by 50%	Express one Rh haplotype*	RHCE (RHDdeleted)
					S/s Normal
					U Weak
Rhnull-regulator	Absent	Absent	Absent	Reduced	Reduced by 70%183	Express both Rh haplotypes	RHAG
					S/s weak
					U Absent
Rhmod	Reduced (variable)	Absent or reduced (variable)	Absent or reduced	Reduced (variable)	Reduced (variable)	Express both Rh haplotypes	RHAG
					S/s Normal
					U Normal/Weak

That is, appear as homozygotes.

Fy glycoprotein.

A possible association between the Fy glycoprotein (synonyms: Duffy, DARC) and the Rh complex is indicated by the Fy5 antigen, which is absent from Fy(a−b−) and RhnullRBCs.60 However, Rhnull RBCs have normal Fya, Fyb, Fy3, and Fy6 antigens, and Fy(a−b−) RBCs have normal Rh antigens. The specific requirements for expression of the Fy5 antigen remain unknown.

Band 3.

Band 3 (synonyms: AE1, anion exchanger, solute carrier family 4 anion exchanger member 1) is a glycosylated protein that is predicted to pass through the RBC membrane 12 or 14 times and is the major anion transporter.61,62 Unlike the proteins described above, band 3 is apparently normal in Rhnull RBCs; however, based on hemagglutination studies, antigens on Rh proteins and on band 3 are decreased in South-East Asian ovalocytic RBCs.63 The molecular defect associated with South-East Asian ovalocytic RBCs results from a deletion of a segment of DNA encoding 9 amino acids located at the boundary of the cytoplasmic N-terminal domain and membrane domain of band 3.64-67 Recent evidence that the expression of endogenous and retrovirally expressed Rh antigens were enhanced following transduction of K562 cells with band 3 suggests that band 3 and Rh proteins associate in erythroid cells.68

Structure of RH and RHAG genes

The genes encoding RhD and RhCcEe are highly homologous, while the gene encoding RhAG is almost 40% homologous. The 3 genes are each composed of 10 exons; RHCE and RHD in tandem encompass 69 kilobases (kb) of DNA (Figure 2), whileRHAG encompasses 32 kb. The RhD protein is encoded byRHD (synonyms: RH30, RH30B, RH30D, RHXIII, RH13); the RhCcEe protein is encoded by RHCE (synonyms: RH30, RH30A, RH30C (RHCE),RHIXB, RH21); and the RHAG glycoprotein is encoded by RHAG (synonyms: RH50, RH50A).

Fig. 2.

RHCE-RHD gene organization.

Organization of exons (E) and introns of RHCE and RHDis shown. Exon sizes are indicated above the line as number of nucleotides, and intron sizes are indicated below the line. A c-specific short tandem repeat (STR) is located in intron 2 ofRHCE and another in intron 6 of RHD. The information used to compile this figure came from the database accession numbers given in the figure.

Fig. 2.

RHCE-RHD gene organization.

Close modal

The intron-exon boundaries of the RHCE gene21 and the complete nucleotide sequences of some RHCE and RHDintrons have been described.69-74 Selected GenBank accession numbers for cDNA are listed in Table 1, and those for introns are given in Figure 2. The intron-exon structure of the RHAGgene also has been defined and is remarkably similar to RHCEand RHD.22,75-77 Several mutations in RHAGhave been described that cause the regulator type of Rh deficiency syndrome (see below).

Evolution of the RH gene family

It was thought that Rh proteins were erythroid-specific and confined to higher vertebrates. However, the discovery of sequence-relatedRHAG homologs in invertebrates suggests otherwise. These homologs have been found as 2 different RHAG-like genes inCaenorhabditis elegans (a nematode; GenBank accession U64 847 and Z74 026)78 and as at least 1 in Geodia cydonium (a marine sponge; GenBank accession Y12 397).79 These genes are predicted to encode proteins with remarkably high (respectively, 46%, 39%, and 47%) amino acid identity to human RhAG. The highest homology is within the transmembrane domains, suggesting a conserved functional role for the RhAG protein family. Recent work has also demonstrated the presence ofRHAG counterparts in mouse (GenBank accession AF065 395; AF057 524-27, AF012 430), macaque (AF058 917) and RHorthologs in chimpanzee (L37 048-50), gorilla (L37 052, L37 053), orangutan (AF012 425), gibbon (L37 051), baboon (AF012 426), macaque (L37 054 570 343), New World monkeys (AF012 427-9, AF021 845) and cow (U59 270).77,80,81

As the invertebrate homologs more strongly resemble human RHAGthan human RH, it is likely that an ancient gene duplication event, estimated to have occurred 250 million to 346 million years ago, caused divergence of RH from RHAG.75Subsequent to the gene duplication, RH and RHAGunderwent different evolutionary pathways.43 A second gene duplication event, being the origin of the human RHCE andRHD genes, occurred much later in a primate ancestor 5 million to 12 million years ago. Based on the evolutionary rates ofRHAG and RH genes in different species, it appears thatRHAG evolved some 2.6 times slower than RH,suggesting that RhAG has a more important functional role than Rh proteins.22,73,77,82

The order of the Rh genes on chromosome 1 is probablyRHCE-RHD.83 (After submission of this manuscript, a paper was published that questions the order of the Rh genes on chromosome 1. Sequencing the intergenic region of the two RH genes suggests that the order may in fact beRHD-RHCE.211) The primordial human Rh haplotype is believed to be Dce, and the other 7 common Rh haplotypes most likely each arose from this gene complex by a single genetic event. The predominant Caucasian D-negative haplotype (dce) probably arose by a deletion of the RHD gene84 from theRHce/RHD gene complex, whereas the DCe haplotype (the most common D-positive haplotype in Caucasians) arose by gene conversion with exon 1 and 2 from RHD replacing the same exons of RHce. The remaining haplotypes arose through point mutations (eg, the E/e polymorphism) or rare recombination events of the various haplotypes.83

Molecular basis of Rh antigens

Since the first descriptions of Rh cDNAs,20,31-33 much effort has been expended in differentiating the molecular bases underlying the antigens of the Rh system. The different genetic mechanisms that give rise to the major clinically relevant Rh antigens are described within this section. These include gene deletion (D-negative phenotype); gene conversion (C/c polymorphism); antithetical missense mutations (E/e); and other missense mutations (VS and V). The RH genes appear to be a source of massive diversity, and combinations of these different genetic rearrangements abound among all racial groups. We have selected examples of Rh polymorphisms that are of clinical significance and have been defined at the molecular level. Figures 3-6 detail the molecular basis of published examples of Rh variants. Enthusiastic readers requiring more data regarding Rh variants should consult references.16,25,85,86

D antigen

The D antigen is a collection of conformation-dependent epitopes along the entire RhD protein. While in most D-negative Caucasians there is a deletion of RHD, in other populations (notably Japanese and African blacks) the D-negative phenotype is associated with a grossly normal RHD, and the reason for the lack of expression of the D antigen is not known (except in Africans; see later). Figure 3 depicts the molecular basis of some D-negative phenotypes.70,74,84,87-89

Fig. 3.

Rearrangements at the Rh locus giving rise to D-negative and Rh deletion haplotypes.

The structures of the RH locus (located at 1p34-36) that has been defined in various D-negative phenotypes and rare Rh antigen deletion phenotypes are depicted. Each RH gene is represented as 10 boxes, each box representing an exon, where RHCE is shown as gray, RHD as black. Crosshatched boxes depict silent RHDalleles (eg, RHD Q41 X ). The positions of microinsertions or deletions of DNA that cause or are indicative of D-negative phenotypes are shown as triangles. Because exon 8 ofRHCE and RHD are of identical sequence and their origins are not possible to define, they are shaded according to the gene loci position. The significance of these rearrangements, and their impact in particular on molecular genotyping, is discussed within the text. Sources for the information in this figure: DCW − (AM)184; DCW − (Glo)185; D−− (LM)186; D−− (Gou)186; D−− (SH)72; D−− and Evans+ D•• (JD)187; Evans+ D•• (AT)69; Evans+ D•• (Dav)186; Dc− (Bol)186; Dc− (LZ)188; Ce70,74,149; r”G(SF)105,140; (Ce)Ce184; (C)ceS VS+ (Donor 1077) V−r'S 29;98;104; Amorph Rhnull (BK/DR)176,189; Amorph Rhnull (DAA)177; CML.179

Fig. 3.

Rearrangements at the Rh locus giving rise to D-negative and Rh deletion haplotypes.

Close modal

People whose RBCs have an altered form of RhD protein (partial D) may make alloanti-D. Such RBCs, depending on which D epitopes are altered, are agglutinated by a proportion of anti-D reagents. Figure4 summarizes the molecular changes that are associated with partial D antigens.

Fig. 4.

Molecular bases of partial D phenotypes.

The different alleles of RHD that cause partial D phenotypes are depicted here graphically. The genetic structure of each partial DRHD 10-exon gene is shown, as are associated low-incidence antigen(s) and the estimated gene frequency. RHD (ie, wild type) exons are shown as black boxes; where they have been replaced byRHCE equivalents is shown as white boxes. Missense mutations are indicated within the exon where they occur. We have used the original Roman numeral notation (ie, DII to DVII) and the more recent 3-letter notation (eg, DFR, DBT) for the different D categories. Where partial D phenotypes have identical (or very similar) serologic profiles but different genetic backgrounds, we have adapted the classification originally described by Mouro et al190 to describe different DVIphenotypes (types I and II). Thus, we depict DIV types I to IV, DV types I to VI; DVI types I to III, and DFR types I and II. We use DVa to indicate the presence of the DW antigen and DV to represent samples that have a similar molecular background but that either do not express the DW antigen or have not been tested for this antigen.Few = 1 to 10 examples. Many = 11 or more examples as indicated by serological testing. DVII is common (1 in 900) in the German population.191 Under “Ethnic Origin,” B = black, C = Caucasian, and J = Japanese. The information used for the point mutations used in this figure are as follows: D+G−106; DNU and DII192; DHMi92; DVII193; DVa71,194 DFW195; DHR.196 The information used for the rearrangements in this figure was obtained from the following: DIIIa197; DIIIb106; DIIIc 198; DIVa type I 194; DIVbtype II194; DIVb type III92; DIVb type IV195; DVa type I194; DVa type II194; DV type III102; DVa type IV156; DV type V156; DVtype VI156; DVI type I199,200; DVI type II190; DVI type III71; DFR type I194; DFR type II201; DBT type I202; DBT type II203; ARRO-1204; DCS205.

Fig. 4.

Molecular bases of partial D phenotypes.

Close modal

Analysis of genes encoding the weak D phenotype (previously known as DU) showed a normal RHD sequence but a severely reduced expression of RHD messenger RNA (mRNA), suggesting a defect at the level of transcription or pre-mRNA processing.70,90 More recently, RHD transcripts from people whose RBCs express a weak form of the D antigen were found to have missense mutation(s) within the predicted transmembrane or cytoplasmic domains of RhD (Figure5).91,92 RBCs with some weak D antigens may not be agglutinated by all monoclonal anti-D. People whose RBCs express this type of weak D antigen do not make anti-D.

Fig. 5.

Molecular basis of weak D phenotypes.

This figure depicts missense mutations in the RHD gene associated with weak D phenotypes.92,153 The locations of these mutations on the predicted topology of the RhD protein are depicted as checkered ovals; the D-specific amino acids are shown as open ovals. Most of the missense mutations are located within nonconserved membrane spans (gray) and cytoplasmic regions. Regions of conserved Rh protein family sequence are indicated as black rectangles.

Fig. 5.

Molecular basis of weak D phenotypes.

Close modal

CcEe antigens

The RhC/c and RhE/e polymorphisms are caused by nucleotide substitutions in RHCE.28,93 While 6 nucleotide substitutions causing 4 amino acid changes (Cys16Trp; Ile60Leu; Ser68Asn; Ser103Pro) are associated with the C to c polymorphism (Figure 6), only the Ser103Pro polymorphism strictly correlates with C/c antigenicity.94 However, Pro102 appears to be a critical part of the c antigen.95,96The presence of 2 adjacent proline residues (102 and 103) would be expected to form a relatively rigid structure that is resistant to changes in nearby amino acid residues and may explain the relatively low number of c variants as compared with other Rh antigens. It has been generally accepted that a single nucleotide substitution is sufficient for expression of the E to e polymorphism (Pro226Ala). However, variants of the e antigen have been described,97showing that the requirements for expression of the e antigen are not fully understood. For example, the presence of Val at residue 245 instead of Leu,29,98,99 a deletion of Arg at amino acid residue 229,100 or the presence of Cys (instead of Trp) at amino acid residue 16 101 affects the expression of the e antigen. The molecular basis of partial E antigens (categories I, II, and III, and DV type III) has been determined and are shown in Figures 4 and 6.102,103

Fig. 6.

Changes in RHCE.

Amino acids encoded by RHCE are shown by gray boxes, and those encoded by exons from RHD are shown by black boxes. The amino acids associated with E/e and C/c antigens28,93 are shown at the top, and single amino acid changes associated with variant forms of RhCE are shown in the middle. The bottom portion of the figure shows rearrangements of the RHCE and associated antigens. Polymorphism that does not have a 100% correlation with expression of c and C antigens. The information depicted in this figure was obtained from the following sources: Point Mutations35,98,99,104,185,206; Rearrangements DHAR 207; rG208;R¯¯ N90; E Cat II and III185; and Variant e100,101.

Fig. 6.

Changes in RHCE.

Close modal

VS and V antigens

The imultaneous presence of 2 low-incidence antigens (VS and V) occurs with a single amino acid substitution (Leu245Val) that is predicted to be within a transmembrane domain (Figure6).104 The V antigen (in the presence of VS) is not expressed when another transmembrane amino acid substitution is present at residue 336 (Gly→Cys) (Figure 3).98,104 The membrane location of residues 245 and 336 illustrate that Rh antigen expression is affected significantly by nonexofacial amino acids and suggests that the prediction of some Rh epitope expression cannot be based solely on externalized residues.

G antigen

RhD and RhC proteins carry the G antigen, which is associated with residues in the second extracellular loop encoded by exon 2.105,106 In DVIcE (DVI type I) RBCs, which are predicted to have a hybrid RhD (exons 1-3)–RHCE (exons 4 and 5)–RhD (exons 6-10) protein, the G antigen was not detected by 1 of 2 monoclonal anti-G.107 Thus, it would appear that the G antigen is conformation-dependent and not solely dependent on the second external domain of RhC(e/E) or RhD proteins.

Rh variants

Rh-variant phenotypes arise through at least 4 mechanisms: (1) rearrangements of the tandemly arrangedRHCE and/or RHD (Figures 3, 4, and 6); (2) point mutation(s) in either gene causing amino acid change(s), with subsequent loss of some epitopes and/or expression of a low-incidence antigen; (3) nonsense mutations, and (4) deletion of nucleotides causing a frameshift and premature stop codon. There is some evidence that there are recombination hot spots due to Alu IV elements in the RH genes.72,108

Rearranged RHCE genes, associated with D−− and D••, ablate expression of C, c, E, and e antigens, while the D antigen expression is exalted to the extent that immunoglobulin (Ig) G anti-D can agglutinate the RBCs in saline.109 It is now clear that this increased expression is due to a large insert ofRHD into RHCE in tandem with a RHD gene (Figure3). In DCW− and Dc− phenotypes, the region of the RHCE gene encoding the E/e antigen is replaced by an RhD equivalent with loss of E/e antigenicity (Figure 3). While these appear as RHCE deletion phenotypes at the protein level, they are encoded by rearranged RHCE and thus are RHCE-depleted.

Low-incidence antigens associated with partial D antigens.

Low-incidence antigens associated with some partial D phenotypes are due to novel structures on the RBC surface and are useful markers for the identification of the partial D (Figure 4).110 A few low-incidence antigens are associated with more than 1 molecular background, eg, the FPTT (Rh50) antigen is expressed on DFR, RoHar, and DIVa(C)− phenotype RBCs; the Rh32 antigen is expressed on DBT andR¯¯NRBCs.The Evans antigen is expressed on D••, and a weak form of Evans is present on DIVb RBCs. RBCs expressing Rh23 or Rh32 possess an antigen (Rh23/32) present on both phenotypes.111In these cases, it is likely that external surfaces of the altered proteins have localized similarities.

RhD epitope mapping

Partial D antigens were classically identified by testing the RBCs with well-characterized polyclonal anti-D made by other people with partial D phenotypes and, also, by testing the patient's anti-D against RBCs with known partial D antigens. Human monoclonal antibodies are now being used to classify partial D antigens in terms of expressed epitopes. The original model consisted of 8- and 9-epitope D (epD)112,113 but has been expanded to consist of 16,110 30,114 and 37 epitopes.115 When using monoclonal anti-D to define D epitopes, it is important to perform the testing at the correct pH, temperature, ionic strength, and antibody concentration; to use RBCs that have been stored appropriately; and to include controls.110,114 Most D epitopes are conformation-dependent and may be influenced by other proteins and lipids in the RBC membrane. Indeed, only 1 monoclonal anti-D has been described that reacts strongly by immunoblotting, implying that the epitope it recognizes may be linear.116

Predictions as to the location of various D epitopes have been based on which epitopes are absent from RBCs with a partial D for which the molecular basis is known.117,118 However, the absence of a D epitope may not always be a direct result of the change in molecular structure, and the presence of Rh proteins encoded by cis andtrans genes can effect the binding of certain monoclonal anti-D. For example, R0Har and DVado not have any RHD exons in common, but they have overlapping reactivity with monoclonal antibody anti-D, demonstrating the difficulty of correctly defining the molecular basis of D epitopes. A model proposed by Chang and Siegel119 suggests that anti-D are essentially similar in that they react with the basic footprint of the D protein. In this model, a change in the footprint, induced by an amino acid substitution or a hybrid protein, is predicted to interfere with binding of anti-D. The involvement of certain residues for binding of monoclonal anti-D has been investigated by site-directed mutagenesis (SDM), which showed that incorporation of 3 D-specific amino acids (Asp350, Gly353, and Ala354) into an RhcE construct generated some epD3 and epD9 expression,120,121 and incorporation of 9 exofacial D residues generated epitopes that were recognized by 40 of 50 monoclonal anti-D.122 These data argue that at least some D epitopes are spatially distinct. However, SDM studies have not yet addressed the impact of amino acids located within the lipid bilayer or on the cytoplasmic side of the RBC membrane. Accurate determination of the contact points of interaction(s) between antigen and antibody awaits crystallographic data.

Clinical aspects

Clinical complications result from RBC destruction due to the interaction of an alloantibody with RBCs carrying the corresponding antigen. The D antigen is highly immunogenic and induces an immune response in 80% of D-negative persons when transfused with 200 mL of D-positive blood.123 For this reason, in most countries D typing is performed routinely on every blood donor and transfusion recipient so that D-negative patients receive D-negative RBC products. Consequently, clinical complications due to mismatched transfusions are infrequent. In contrast, despite the use of immunosuppressive therapy with anti-D immunoglobulin prophylaxis, D alloimmunization in pregnancy still occurs.

Alloantibodies

Alloantibodies that recognize Rh antigens are usually IgG and react by the indirect antiglobulin test. This is a test in which RBCs are incubated in serum, washed to remove free immunoglobulin, and then exposed to an antiglobulin reagent that is formulated to detect the cell-bound IgG. The end point of the test is hemagglutination. Alloantibodies in the Rh blood group system can cause destruction of transfused RBCs and of fetal RBCs in hemolytic disease of the newborn (HDN). People whose RBCs have a rare deleted Rh phenotype (Rhnull, D−−) readily make alloantibodies. People with the Rhnull phenotype of amorph or regulator type can make anti-Rh29 (an antibody to “total” Rh), anti-Rh27 (an antibody to the RhCc/Ee protein), anti-D, anti-C, or a mixture of specificities. Transfusion of a patient with anti-Rh29 is a problem because only Rhnull RBCs will be compatible: People with the Rhnull phenotype are not only rare, but they have a compensated hemolytic anemia and are therefore unlikely to meet predonation criteria.124 People with either the D−−, D••, DCW−, or Dc− phenotype make anti-Rh27. A patient with anti-Rh27 also represents a transfusion conundrum because only RBCs with a deleted phenotype will be compatible.

Autoantibodies

An autoantibody is one that reacts with an antigen on the antibody maker's own RBCs. Autoantibodies that react optimally at 37°C are present in the serum of about 80% of patients with warm autoimmune hemolytic anemia.125 Although most of these autoantibodies appear to be “nonspecific,” many have specificity to an Rh antigen, notably to e. Rarely is the specificity clear-cut, but the autoantibody commonly reacts more weakly with antigen-negative RBCs than with antigen-positive RBCs; however, in these cases, transfused antigen-negative RBCs only rarely survive better than antigen-positive RBCs.123 Autoantibodies in serum from patients with warm autoimmune hemolytic anemia may be nonreactive only with Rhnull and D−− RBCs (autoanti-Rh27), or only with Rhnull RBCs (autoanti-Rh29). In such cases, antigen-negative blood will not be available, and transfusion with antigen-positive RBCs should not be withheld if the patient has life-threatening anemia.125,126 In most cases, the autoantibody is equally reactive with all RBCs tested—whether from donors or antibody detection/identification kits. Thus, in the clinical setting, it is important to perform tests to ensure that the patient's serum does not have potentially clinically significant alloantibodies underlying the autoantibodies before transfusing incompatible RBCs. Detection and identification of such antibodies is required to prevent transfusion reactions but is beyond the scope of this review. For more information, see a current textbook on laboratory aspects of transfusion medicine.125-127

Partial and weak D phenotypes

As described earlier, people whose RBCs have a weak D phenotype (quantitative D variant) do not make anti-D, whereas people whose RBCs have a partial D phenotype (qualitative D variant with or without weakening of the D antigen) can make alloanti-D. This presents a different problem depending on whether the person is a donor or a patient. For donors, detection of weak and partial D antigens would eliminate the possibility of immunization should such blood be transfused to a true D-negative patient. However, historical data show that weakly expressed D antigens are most unlikely to be immunogenic. For transfusion recipients and pregnant women, it is common practice to use a procedure that will classify RBCs with a weak D antigen or some partial D antigens as D-negative. Thus, blood donated from such a person should be labeled as D-positive (Rh-positive), but the same person should be listed as D-negative (Rh-negative) when they are recipients in need of transfusion. The transfusion recipient will receive D-negative RBC products, and the pregnant woman will receive prophylactic Rh immunoglobulin, thereby preventing alloimmunization. Although a pregnant woman with the DVI partial phenotype may make alloanti-D, this has rarely caused a clinical problem to a D-positive fetus.128 In the autologous transfusion setting (in which the person is both the donor and patient), the above policy can cause confusion because partial D RBCs may be typed as D-positive at the donor center but D-negative at the hospital. In practice, it is difficult to distinguish RBCs with the DVI phenotype from other weak D; however, this now can be accomplished by immunoblotting with the unique anti-D, LOR-15C9.129

Rh and hemolytic disease of the newborn

HDN is caused by maternal IgG antibody crossing the placenta, binding to the fetal antigen-positive RBCs, and initiating their destruction, thereby causing anemia. Prior to the use of prophylactic Rh immunoglobulin, anti-D frequently caused fetal brain damage due to increased levels of bilirubin (kernicterus) and even death (erythroblastosis fetalis). Despite the widespread use of prophylactic Rh immunoglobulin, a significant number of women still become alloimmunized during pregnancy for a variety of reasons, including nonadministration of Rh immunoglobulin, unrecognized miscarriage, leakage of fetal RBCs into the maternal circulation late in pregnancy, and exposure to maternal D-positive RBCs while in utero (grandmother effect).130

The D antigen accounts for about 50% of cases of maternal alloimmunization; the remainder is due mainly to incompatibility to K, c, C/G, E, and Fya antigens and to low incidence antigens in Rh, MNS, and Diego blood group systems.131-133Therefore, feto-maternal Rh incompatibility still represents the major cause of HDN. Ultraviolet phototherapy and, occasionally, exchange transfusion or even intrauterine transfusion may be required. Invasive procedures are used as a “last option” in monitoring and treating HDN, because they may cause further leakage of fetal RBCs into the maternal circulation. Measures such as determination of the optical density of amniotic fluid and functional assays (ADCC, MMA, chemiluminescence) have been used to monitor at-risk pregnancies and to identify cases requiring treatment (for review, see Zupanska134). With current molecular technology, it is possible to perform analyses on fetally derived DNA to predict the blood type of a fetus.

Interestingly, a fetus that is ABO incompatible with the maternal anti-A/B is less likely to have HDN due to anti-D, presumably due to rapid removal of the ABO-incompatible RBCs by the naturally occurring anti-A/B. Also, because the number of copies of the D antigen per RBC is higher in the R2 haplotype (range, 14 000 to 16 000) than in the R1 haplotype (range, 9000 to 14 600), fetuses whose RBCs are R2 have more severe anemia than their R1counterparts.123 There is also evidence that male fetuses have more severe HDN than female fetuses.135

Rh immunoglobulin prophylaxis in the prevention of HDN.

The immunologic mechanism responsible for preventing production of maternal anti-D following administration of prophylactic Rh immunoglobulin may be due, at least in part, to antigen blocking and central inhibition of the immune response by negative feedback in the spleen (for review, see Bowman130). In some instances, recommendations have been made to administer anti-D to partial D-phenotype mothers (eg, DVI and DBT phenotypes) following the birth of D-positive babies.110,136 In Europe, anti-D reagents are selected to deliberately type DVI mothers as D-negative and, thus, ensure that such mothers would automatically receive prophylactic Rh immunoglobulin therapy following pregnancy.

Prophylactic Rh immunoglobulin preparations for this purpose are usually for intramuscular injection. However, products approved also for intravascular injection are used for the treatment of idiopathic thrombocytopenia.137,138

Legislative restrictions for immunization of D-negative volunteers with accredited D-positive RBCs are partly responsible for the declining source of polyclonal anti-D for prophylaxis. Thus, clinical trials have explored the possibility of using human monoclonal anti-D to prevent anti-D alloimmunization;139 however, the in vivo use of monoclonal antibodies derived from EBV-transformed cells remains controversial. It is possible that recombinant forms of anti-D can be prepared as an injectable prophylactic product.

Prenatal Rh genotyping

When a pregnant woman has a potentially clinically significant alloantibody and the father of the fetus is phenotypically heterozygous for the gene encoding the corresponding antigen (or is unknown), prenatal determination can be considered. The potential benefits of identifying a fetus whose RBCs are predicted to be antigen-negative is enormous in that the need for further invasive techniques is diminished. Fetal DNA can be obtained from amniocytes, chorionic villi, vaginal swabs, and mother's blood (see later). Following cloning and sequencing of RHCE and RHD, many polymerase chain reaction (PCR)-based tests to analyze DNA prepared from amniocytes have been reported (for recent review, see Flegel86). However, the genetic diversity of the Rh genes, particularly among blacks and Japanese, has reduced the clinical utility of this approach because false-negative and false-positive results can occur. Prenatal diagnosis of fetal RHD status exploits structural differences between theRHD and RHCE genes and is based on the assumption that D-negative individuals have a deleted RHD gene. As the knowledge regarding the molecular basis of partial D antigens evolved, use of multiplex,70,86,140,141heteroduplex,142,143 and multiple sequence-specific PCR reactions144,145 have replaced the single exon genotyping assays32,146,147 in an attempt to avoid “false-negative” typing of a fetus with a partial D antigen. However, because HDN in a fetus whose RBCs have a partial D antigen is rare,148 the clinical value of RHD multiplex analysis may only have marginal added value.

All current RhD genotyping assays will mistype people whose RBCs are D-negative and yet carry an intact, nonfunctional RHD. Such people have been described in Caucasians (rare),70 African blacks (common),89,144 and Asians (common).74,144 Molecular genotyping will have limited clinical utility in populations where the presence of nonexpressedRHD is frequent. The molecular backgrounds of these D-negative phenotypes are beginning to emerge: In 2 Caucasians expressing the dCe phenotype, 1 had an in-frame stop codon in exon 1 of the RHDgene70 and the other a deletion of 4 nucleotides in exon 4.149 Very recently, the molecular basis of the major silent RHD allele (namedRHDψ) found in persons of African ancestry has been defined.150,RHDψ has a 37–base pair insertion of DNA, being a duplication of the intron 3/exon 4 boundary, and has missense mutations in exon 5 and a nonsense and missense mutation in exon 6. The Del phenotype (ie, D antigen is detectable only by adsorption-elution tests) was thought to have a deletion ofRHD;151,152 however, a deletion of 1013 base pairs encompassing intron 8, exon 9, and intron 9 has been observed (Figure5).153

Clearly, knowledge of the ethnic group of both parents is helpful in the selection of appropriate genotyping tests. Wherever possible, to limit the gene pool, concurrent analyses of maternal and paternal blood group phenotypes and genotypes should be performed. It is worth noting that samples that have been used for clinical automated instruments are often contaminated with blood from previous tests.144,154

As molecular analysis becomes more common, it is worth remembering that some D variants may be more common than previously thought. An example of this is the hybrid gene encoding the DIIIa phenotype, which has recently been shown to be present in 18% of blacks in New York and 28% of blacks from Brazil.155 Furthermore, a similar pattern of reactivity may be obtained with monoclonal anti-D in tests with RBCs from people with different Rh genes. This is illustrated by the large number of molecular events associated with DVa (or DV-like) samples as defined by the pattern of reactivity with monoclonal anti-D.156 Not all of the molecular events give rise to the DW antigen, whose presence on RBCs is required for DVacategorization.110

Although hemolytic disease due to Rh antibodies other than anti-D is less frequent, PCR-based tests have been designed to defineRHCE alleles using fetally derived DNA.157-159 Most of these are relatively straightforward; however, genotyping C in the presence of D is difficult because RHC(E/e) and RHDhave identical sequences in exons 1 and 2. RhC typing is possible by exploitation of a polymorphism in intron 2 of RHCE, which involves a 109-base pair insert of DNA in RHC(E/e) but notRhc(E/e) or RHD.94,159

Noninvasive prenatal Rh genotyping.

It is now possible to obtain fetally derived DNA using noninvasive procedures. Fetally derived RHD has been detected using nested PCR analysis on genomic DNA (gDNA) extracted from maternal peripheral blood or plasma160-163 or from transcervical samples.164-166 An alternative approach uses cDNA templates derived by reverse transcriptase–PCR from maternal peripheral blood and detection of fetal RhD mRNA targets.167 All noninvasive procedures have limited value because there is no suitable way to assess the presence of fetal cells in a given sample and, thus, negative results cannot be interpreted with confidence. Nevertheless, the fact that fetally derived Rh mRNAs and gDNA can be detected in maternal blood indicates that this area of prenatal diagnosis may soon have an impact. However, it is possible that fetal-nucleated RBCs are the most pertinent target cell type for noninvasive diagnosis168,169 because other fetally derived CD34+ cells have been detected in maternal blood for as long as 27 years postpartum169 and thus could interfere with analyses in women who have had multiple pregnancies.

Rh and other disease states

Rhnull disease.

RBCs from people who have the Rhnull phenotype (synonyms: Rhnull syndrome, Rhnull disease) lack Rh proteins and, thus, Rh antigens. This phenotype is rare (approximately 1 in 6 × 106 individuals)170 and most often results from a consanguineous mating. The syndrome is associated with stomatocytosis, spherocytosis, increased osmotic fragility, altered phospholipid asymmetry, altered cell volume, defective cation fluxes, and elevated Na+/K+ ATPase activity.13,14,171-173 Rhnull RBCs may have a shortened in vivo survival, and the person may have a mild compensated hemolytic anemia.

There are 2 types of Rhnull, amorph and regulator, that historically were classified based on their pattern of inheritance. It is now known that the amorph type is the result of a molecular change in RHCE in tandem with a deleted RHD (Figure 3),whereas the regulator type is associated with a molecular defect inRHAG (Figure7).22,76,174-177 Table 2summarizes the characteristics of the 2 types of Rhnullphenotypes and compares them with the Rhmodphenotype, in which the Rh antigens are suppressed. While RhAG is apparently critical for the correct assembly of the Rh proteins in the RBC membrane, RhAG by itself can form stable complexes, albeit in reduced quantity, in the absence of Rh proteins.22,58

Fig. 7.

Localization of molecular defects on RhAG.

The regulator type of Rhnull is associated with 2 mutantRHAG genes (homozygote or double heterozygote). The mutations include splice site/frameshift alterations and missense mutations (gray circles). The missense changes predominantly occur within conserved Rh protein family domains (black rectangles), within membrane-spanning regions. It is thought that missense mutations affect either RhAG-RhAG associations/RhAG-Rh protein assocations, resulting in an absence of the Rh protein family from mature RBC membranes. The Rhmodphenotype is associated with missense mutations (crosshatched circles), which lead to a marked reduction of the RhAG-Rh protein complex in mature RBC membranes. The initials refer to the probands. The information used in this figure was obtained from the following: SM209; SF, JL174; AL177; YT27,175; VL174; HT 210; TT, AC22; TB174; WO210.

Fig. 7.

Localization of molecular defects on RhAG.

Close modal

Myeloid leukemia

Patients with acute or chronic myeloid leukemia, myeloid metaplasia, polycythemia, or myelofibrosis occasionally have 2 populations of RBCs of different Rh type. In some cases, a loss of Rh antigens is associated with chromosome aberrations.178 Recent analysis of blood from a D-positive patient with CML who became D-negative for the 3 years that she was studied revealed a single base deletion in exon 4 of RHD that occurred by somatic mutation.179

Discussion

Considerable progress has been made in our understanding of the molecular basis of Rh and other blood group antigens in the past 10 years. Despite this, our knowledge concerning the function of many of the components in the RBC remains speculative. The Rh protein complex is a prime example of this; it is a major red cell protein of considerable clinical importance, yet our understanding of its functional significance in human RBCs and other animals relies almost entirely on circumstantial evidence.

The Rh blood group system consists of numerous antigens that are located on variant forms of RhD and RhCE proteins. These proteins form a core complex in the erythrocyte membrane with a glycosylated homolog (RhAG) and are only expressed when it is present. RhD, RhCE, and RhAG associate with other membrane proteins (LW, IAP, GPB, Duffy, and band 3) to form a large complex. Although the function(s) of these proteins has not been defined, it is possible that the complex forms a concerted transporter. The genes encoding the Rh proteins (RHCE andRHD) are highly homologous and adjacent on the short arm of chromosome 1, while the gene encoding RhAG (RHAG) is nearly 40% homologous and is located on the short arm of chromosome 6. Although the molecular basis associated with many of the Rh antigens is known, the actual epitopes have not been defined, but it is apparent that most of the Rh antigens are conformation-dependent. The molecular knowledge is increasingly being used in the clinical setting. However, the allelic diversity in this system is a potential problem for reliable genotyping by PCR-based assays. Hemagglutination is still a powerful, practical, and economical test with a specificity and sensitivity that is appropriate for clinical applications. However, the use of hemagglutination in conjunction with molecular techniques undoubtedly will lead to insights that can enhance approaches for the treatment of Rh incompatibility. Further understanding of the immunologic responses to the Rh antigens will be of importance in the treatment of hemolytic disease, and detailed epitope maps involving serologic, molecular, and protein crystallographic studies of the Rh proteins will contribute to this objective.

Acknowledgments

We thank Christine Lomas-Francis, Narla Mohandas, Olga Blumenfeld, Geoff Daniels, Michael J. A. Tanner, Jill Storry, and Karina Yazdanbakhsh for reading the manuscript and giving helpful suggestions. Neil Avent thanks Willy Flegel, Giorgio Matassi, and Tim Kemp for providing manuscripts prior to publication. We also thank Robert Ratner for preparing the manuscript and cataloging the references.

Supported in part by a National Institutes of Health Specialized Center of Research (SCOR) grant in transfusion medicine and biology HL54 459.

Reprints:Marion E. Reid, Immunochemistry Laboratory, New York Blood Center, 310 East 67th St, New York, NY 10021; e-mail:.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 U.S.C. section 1734.

References

An unusual case of intragroup agglutination.

JAMA.

113

1939

126

127

An agglutinable factor in human blood recognized by immune sera for rhesus blood.

Proc Soc Exp Biol Med.

1940

223

Observations on the Rh agglutinogen of human blood.

Am J Clin Pathol.

1942

545

552

A human ‘D-like’ antibody.

Nature.

198

1963

596

597

et al

Blood group terminology 1995: ISBT working party on terminology for red cell surface antigens.

Vox Sang.

1995

265

279

A review of Rh serology and presentation of a new terminology.

Transfusion.

1962

287

312

Genetic model for the Rh blood-group system.

Proc Natl Acad Sci U S A.

1973

1303

1307

Review of Rh serology: eight new antigens in nine years.

Haematologia.

1972

113

120

Rh nomenclature.

Transfusion.

1979

487

Isolation of membrane components associated with human red cell antigens Rh(D), (c), (E) and Fy.

Nature.

295

1982

529

531

Molecular identification of the human RhO (D) antigen.

FEBS Lett.

140

1982

The identification of specific Rhesus polypeptide blood group ABH-active glycoprotein complexes in the human red-cell membrane.

Biochem J.

244

1987

735

741

Molecular biology of the Rh antigens.

Blood.

1991

551

563

Biochemical aspects of the blood group Rh (rhesus) antigens.

Baillieres Clin Haematol.

1993

401

422

Identification of Rh polypeptide and Rh polypeptide/Rh glycoprotein complexes.

Biotest Bull.

1997

409

413

Molecular insights into the Rh protein family and associated antigens.

Curr Opin Hematol.

1997

103

Isolation of cDNA clones for a 50 kDa glycoprotein of the human erythrocyte membrane associated with Rh (rhesus) blood-group antigen expression.

Biochem J.

287

1992

223

228

Topology and organization of human Rh (rhesus) blood group-related polypeptides.

J Biol Chem.

269

1994

6417

6423

et al

Immunochemical analysis of the human erythrocyte Rh polypeptides.

J Biol Chem.

271

1996

14,233

14,239

cDNA cloning of a 30 kDa erythrocyte membrane protein associated with Rh (Rhesus)-blood-group-antigen expression.

Biochem J.

271

1990

821

825

Organization of the gene (RHCE) encoding the human blood group RhCcEe antigens and characterization of the promoter region.

Genomics.

1994

The human Rh50 glycoprotein gene—structural organization and associated splicing defect resulting in Rhnull disease.

J Biol Chem.

273

1998

2207

2213

et al

Localization of the C termini of the Rh (rhesus) polypeptides to the cytoplasmic face of the human erythrocyte membrane.

J Biol Chem.

267

1992

15,134

15,139

et al

Immunochemical characterization of rhesus proteins with antibodies raised against synthetic peptides.

Blood.

1993

669

676

et al

Insights into the structure and function of membrane polypeptides carrying blood group antigens.

Vox Sang.

74(suppl 2)

1998

Mammalian red cell membrane Rh polypeptides are selectively palmitoylated subunits of a macromolecular complex.

J Biol Chem.

267

1992

5569

5574

Rh50 glycoprotein gene and Rhnull disease: a silent splice donor is trans to a Gly279—>Glu missense mutation in the conserved transmembrane segment.

Blood.

1998

1776

1784

Molecular genetic basis of the human Rhesus blood group system.

Nature Genet.

1993

Serotype switching in a partially deleted RHD gene.

Vox Sang.

1994

397

401

Expression of RHD and RHCE gene products using retroviral transduction of K562 cells establishes the molecular basis of Rh blood group antigens.

Blood.

1996

2968

2973

et al

Molecular cloning and primary structure of the human blood group RhD polypeptide.

Proc Natl Acad Sci U S A.

1992

10,925

10,929

Molecular cloning of RhD cDNA derived from a gene present in RhD-positive, but not RhD-negative individuals.

Blood.

1993

651

655

et al

Molecular cloning and protein structure of a human blood group Rh polypeptide.

Proc Natl Acad Sci U S A.

1990

6243

6247

Regarding the size of Rh proteins.

Blood.

1991

411

Molecular basis of the RhCW (Rh8) and RhCX (Rh9) blood group specificities.

Blood.

1995

1196

1201

Isolation of a new cDNA clone encoding an Rh polypeptide associated with the Rh blood group system.

Hum Genet.

1993

157

162

The Rh polypeptide is a major fatty acid-acylated erythrocyte membrane protein.

J Biol Chem.

263

1988

18,193

18,196

Effects of modulating erythrocyte membrane cholesterol on Rho(D) antigen expression.

Biochem Biophys Res Commun.

1980

887

893

Studies on the glycoprotein associated with Rh (rhesus) blood group antigen expression in the human red blood cell membrane.

J Biol Chem.

269

1994

6410

6416

The expression of human blood group antigens during erythropoiesis in a cell culture system.

Blood.

1999

4425

4435

On a search for Rhesus antibodies in very young foetuses.

Arch Dis Child.

1955

232

233

The Rh (rhesus) blood group polypeptides are related to NH4+ transporters.

Trends Biochem Sci.

1997

460

461

The members of the RH gene family (RH50 and RH30) followed different evolutionary pathways.

J Mol Evol.

1999

151

159

The MEP2 ammonium permease regulates pseudohyphal differentiation in Saccharomyces cerevisiae.

EMBO J.

1998

1236

1247

The red cell LW blood group protein is an intercellular adhesion molecule which binds to CD11/CD18 leukocyte integrins.

Eur J Immunol.

1995

3316

3320

Applied Blood Group Serology.

1998

Montgomery Scientific Publications

Durham, NC

Human Blood Groups.

1995

Blackwell Science Ltd

Oxford, England

The LW blood group: a review.

Immunol Commun.

1980

225

242

et al

Identification and partial characterization of the human erythrocyte membrane component(s) that express the antigens of the LW blood-group system.

Biochem J.

234

1986

649

652

Integrin-associated protein: a 50-kD plasma membrane antigen physically and functionally associated with integrins.

J Cell Biol.

111

1990

2785

2794

Isolation and characterization of CD47 glycoprotein: a multispanning membrane protein which is the same as integrin- associated protein (IAP) and the ovarian tumour marker OA3.

Biochem J.

304

1994

525

530

In vivo expression of alternatively spliced forms of integrin-associated protein (CD47).

J Cell Sci.

108

1995

3419

3425

Integrin-associated protein is a receptor for the C-terminal domain of thrombospondin.

J Biol Chem.

271

1996

A 50-kDa integrin-associated protein is required for integrin-regulated calcium entry in endothelial cells.

J Biol Chem.

268

1993

19,931

19,934

Identification of a cell-surface antigen produced by a gene on human chromosome 3 (cen-q22) and not expressed by Rhnull cells.

Am J Hum Genet.

1987

1061

1070

et al

Monoclonal antibodies that recognize different membrane proteins that are deficient in Rhnull human erythrocytes: one group of antibodies reacts with a variety of cells and tissues whereas the other group is erythroid-specific.

Biochem J.

251

1988

499

505

The abundance and organization of polypeptides associated with antigens of the Rh blood group system.

Transfus Med.

1991

et al

Murine monoclonal antibody MB-2D10 recognizes Rh-related glycoproteins in the human red cell membrane.

Transfusion.

1990

222

225

The blood group U antigen is not located on glycophorin B.

Biochim Biophys Acta.

884

1986

337

343

Anti-Fy5, and antibody disclosing a probable association between the Rhesus and Duffy blood group genes.

Vox Sang.

1973

193

199

Molecular and cellular biology of the erythrocyte anion exchanger (AE1).

Semin Hematol.

1993

Topology of the membrane domain of human erythrocyte anion exchange protein, AE1.

J Biol Chem.

274

1999

6626

6633

Selective depression of blood group antigens associated with hereditary ovalocytosis among Melanesians.

Vox Sang.

1977

110

Melanesian hereditary ovalocytes have a deletion in red cell band 3.

Blood.

1991

2785

2786

Defective anion transport activity of the abnormal band 3 in hereditary ovalocytic red blood cells.

Nature.

355

1992

836

838

et al

Molecular basis of altered red blood cell membrane properties in Southeast Asian ovalocytosis: role of the mutant band 3 protein in band 3 oligomerization and retention by the membrane skeleton.

Blood.

1995

349

358

et al

Molecular basis for membrane rigidity of hereditary ovalocytosis: a novel mechanism involving the cytoplasmic domain of band 3.

J Clin Invest.

1992

686

692

Functional cell surface expression of band 3, the human red blood cell anion exchange protein (AE1), in K562 erythroleukemia cells: band 3 enhances the cell surface reactivity of Rh antigens.

Blood.

1998

4428

4438

Genetic recombination at the human RH locus: a family study of the red cell-Evans phenotype reveals a transfer of exons 2-6 from the RHD to the RHCE gene.

Am J Hum Genet.

1996

825

833

et al

Evidence of genetic diversity underlying Rh D-, weak D (Du), and partial D phenotypes as determined by multiplex polymerase chain reaction analysis of the RHD gene.

Blood.

1997

2568

2577

Three molecular structures cause rhesus D category VI phenotypes with distinct immunohematological features.

Blood.

1998

2157

2168

A recombination hot spot in the Rh genes revealed by analysis of unrelated donors with the rare D—phenotype.

Am J Hum Genet.

1996

1066

1073

Investigation of the RH locus in gorillas and chimpanzees.

J Mol Evol.

1996

658

668

et al

The RHD gene is highly detectable in RhD-negative Japanese donors.

J Clin Invest.

100

1997

373

379

Organization of the human RH50A gene (RHAG) and evolution of base composition of the RH gene family.

Genomics.

1998

286

293

Identification of 5' flanking sequence of RH50 gene and the core region for erythroid-specific expression.

Biochem Biophys Res Commun.

243

1998

233

240

Conserved evolution of the Rh50 gene compared to its homologous Rh blood group gene.

Biochem Biophys Res Commun.

249

1998

et al

2.2 Mb of contiguous nucleotide sequence from chromosome III of C. elegans.

Nature.

368

1994

Molecular cloning and primary structure of a Rhesus (Rh)-like protein from the marine sponge Geodia cydonium.

Immunogenetics.

1997

493

498

Sequences and evolution of mammalian RH gene transcripts and proteins.

Immunogenetics.

1999

Gorilla RH-like genes and antigens.

Immunogenetics.

1999

125

133

Molecular Biology and Evolution of Blood Group and MHC Antigens in Primates.

1997

Springer-Verlag

Berlin

Evolution of the human RH (rhesus) blood group genes: a 50 year old prediction (partially) fulfilled.

Hum Mol Genet.

1997

843

850

Genetic basis of the RhD-positive and RhD-negative blood group polymorphism as determined by Southern analysis.

Blood.

1991

2747

2752

Avent ND. The Rhesus blood group system: insights from recent advances in molecular biology. Transfus Med Rev. In press.

Rh phenotype prediction by DNA typing and its application to practice.

Transfus Med.

1998

281

302

Molecular analysis of Rh polypeptides in a family with RhD-positive and RhD-negative phenotypes.

Biochem J.

299

1994

207

211

Three unrelated Rh D gene polymorphisms identified among blood donors with Rhesus CCee (r'r') phenotypes.

Blood.

1994

321

324

Differences between RhD-negative Africans and RhD-negative Europeans.

Lancet.

350

1997

862

863

Molecular basis of the altered antigenic expression of RhD in weak D (Du) and RhC/e in RN phenotypes.

Blood.

1996

4853

4861

et al

RHD genotyping in weak D phenotypes by multiple polymerase chain reactions.

Transfusion.

1998

434

440

Molecular basis of weak D phenotypes.

Blood.

1999

385

393

et al

Sequence analysis of cDNA derived from reticulocyte mRNAs coding for Rh polypeptides and demonstration of of E/e and C/c polymorphisms.

Vox Sang.

1994

203

209

Molecular investigation of the Rh C/c polymorphism [abstract].

Transfus Med.

7(suppl 1)

1997

The Rhesus system.

Molecular Biology and Evolution of Blood Group and MHC Antigens in Primates.

1997

147

218

Springer-Verlag

Berlin

Characterization of the Rh locus of the New World capuchin (Cebus apella) monkey [abstract].

Transfusion

38(suppl)

1998

102S

An invited review: the Rh antigen e, its variants, and some closely related serological observations.

Immunohematology.

1991

et al

Molecular background of VS and weak C expression in blacks.

Transfusion.

1997

Denaturing gradient gel electrophoresis: a novel method for determining Rh phenotype from genomic DNA.

Br J Haematol.

1996

417

421

100

Deletion of Arg229 in RhCE polypeptide alters expression of RhE and CE-associated Rh6 [abstract].

Blood.

90(suppl 1)

1997

272a

101

et al

Altered “e” antigen expression associated with 16Cys in exon 1 of the RHce gene [abstract].

Transfusion.

38(Suppl)

1998

64S

102

Molecular biology of partial D phenotypes.

Transfus Clin Biol.

1996

511

516

103

et al

Heterogeneity of blood group RhE variants revealed by serological analysis and molecular alteration of the RHCE gene and transcript.

Br J Haematol.

103

1998

429

436

104

et al

The VS and V blood group polymorphisms in Africans: a serological and molecular analysis.

Transfusion.

1998

951

958

105

et al

Involvement of Ser103 of the Rh polypeptides in G epitope formation.

Transfusion.

1996

506

511

106

Lack of G blood group antigen in DIIIb erythrocytes is associated with segmental DNA exchange between RH genes.

Br J Haematol.

1995

424

426

107

Rh antigen D: variable expression in DVI phenotypes; a possible subdivision of category VI by a low frequency antigen [abstract].

Transfusion.

29(suppl)

1989

14S

108

Characterization of the recombination hot spot involved in the genomic rearrangement leading to the hybrid D-CE-D gene in the DVI phenotype.

Am J Hum Genet.

1997

808

817

109

A probable deletion in a human Rh chromosome.

Nature.

166

1950

520

521

110

The Rh antigen D: partial D antigens and associated low incidence antigens.

Vox Sang.

1996

123

131

111

Two examples of an inseparable antibody that reacts equally well with DW+ and Rh32+ red blood cells.

Vox Sang.

1998

230

233

112

Demonstration of seven epitopes on the Rh antigen D using human monoclonal anti-D antibodies and red cells from D categories.

Vox Sang.

1989

261

264

113

Further complexities of the Rh antigen D disclosed by testing category DII cells with monoclonal anti-D.

Transfus Med.

1993

114

Monoclonal anti-D specificity and Rh D structure: criteria for selection of monoclonal anti-D reagents for routine typing of patients and donors.

Transfus Med.

1995

171

184

115

Rh serology—Coordinator's report.

Transfus Clin Biol.

1996

333

337

116

et al

A human monoclonal anti-D antibody which detects a nonconformation-dependent epitope on the RhD protein by immunoblotting.

Br J Haematol.

1997

365

374

117

Tentative model for the mapping of D epitopes on the RhD polypeptide.

Transfus Clin Biol.

1996

497

503

118

et al

A structural model for 30 Rh D epitopes based on serological and DNA sequence data from partial D phenotypes.

Transfus Clin Biol.

1996

391

396

119

Genetic and immunological properties of phage-displayed human anti-Rh(D) antibodies: implications for Rh(D) epitope topology.

Blood.

1998

3066

3078

120

Site-directed mutagenesis of the human D antigen: definition of D epitopes on the sixth external domain of the D protein expressed on K562 cells.

Transfus.

1999

121

Use of RhD fusion protein expressed on K562 cell surface in the study of molecular basis for D antigenic epitopes.

J Biol Chem.

274

1999

5731

5737

122

Liu W, Avent ND, Jones JW, Scott ML, Voak D. D epitope localisation using site directed mutagenesis and expression of Rh mutant constructs in K562 cells. Blood. In press.

123

Blood Transfusion in Clinical Medicine.

1997

Blackwell Science

Oxford, England

124

Standards Committee of American Association of Blood Banks

Standards for Blood Banks and Transfusion Services.

1999

American Associations of Blood Banks

Bethesda, MD

125

Acquired Immune Hemolytic Anemias.

1980

Churchill Livingstone

New York

126

Transfusion in the face of autoantibodies.

Red Cell Transfusion: A Practical Guide.

1998

Humana Press

Totowa, NJ

127

Technical Manual.

1999

American Association of Blood Banks

Bethesda, MD

128

Fatal hemolytic disease of a newborn due to anti-D in an Rh-positive Du variant mother.

Transfusion.

1983

129

Use of LOR-15C9 monoclonal anti-D to differentiate erythrocytes with the partial DVI antigen from those with other partial D antigens or weak D antigens.

Immunohematology.

1998

130

The development and use of polyclonal prophylactic anti-D IgG.

Biotest Bull.

1997

503

510

131

Blood group alloantibodies: an assessment of some laboratory practices.

Transfusion.

1977

299

308

132

Multiple red cell transfusions and alloimmunization: experience with 6996 antibodies detected in a total of 159,262 patients from 1985 to 1993.

Arch Pathol Lab Med.

119

1995

133

A retrospective study to determine the risk of red cell alloimmunization and transfusion during pregnancy.

Transfusion.

1993

217

220

134

Assays to predict the clinical significance of blood group antibodies.

Curr Opin Hematol.

1998

412

416

135

Male fetuses are particularly affected by maternal alloimmunization to D antigen.

Transfusion.

1999

169

173

136

Should anti-Rh immunoglobulin be given D variant women?

Br J Haematol.

1989

429

433

137

Intravenous anti-D treatment of immune thrombocytopenic purpura: analysis of efficacy, toxicity, and mechanism of effect [comments].

Blood.

1991

1884

1893

138

et al

Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients.

Blood.

1997

2689

2700

139

et al

Human Rh D monoclonal antibodies (BRAD-3 and BRAD-5) cause accelerated clearance of Rh D+ red blood cells and suppression of Rh D immunization in Rh D- volunteers.

Blood.

1995

1701

1709

140

et al

Genotyping of RHD by multiplex polymerase chain reaction analysis of six RHD-specific exons.

Transfusion.

1998

1015

1021

141

Multiplex PCR analysis of RhD gene.

Lancet.

346

1995

375

376

142

Heteroduplex generator in analysis of Rh blood group alleles.

Clin Chem.

1996

356

360

143

Prenatal analysis of rhesus CcDEe blood groups by heteroduplex generator.

Am J Obstet Gynecol.

176

1997

1084

1089

144

et al

Specificity and sensitivity of RHD genotyping methods by PCR-based DNA amplification.

Br J Haematol.

1997

356

364

145

et al

RHD/CE typing by polymerase chain reaction using sequence-specific primers.

Transfusion.

1997

1020

1026

146

et al

Prenatal determination of fetal RhD type by DNA amplification.

N Engl J Med.

329

1993

607

610

147

Rhesus D: genotyping using polymerase chain reaction.

Blood.

1993

1682

1683

148

Rh immunization by the partial D antigen of category DVa.

Br J Haematol.

1990

537

539

149

The RhD-trait in a white patient with the RhCCee phenotype attributed to a four-nucleotide deletion in the RHD gene.

Blood.

1998

1839

1840

150

et al

An RHD pseudogene containing a 37 bp duplication and a nonsense mutation is present in most Africans with the Rh D-negative blood group phenotype.

Blood.

2000

151

et al

Further analysis of Del (D-elute) using polymerase chain reaction (PCR) with RHD gene-specific primers.

Transfus Med.

1997

227

231

152

RHD gene polymorphisms among RhD-negative Chinese in Taiwan.

Vox Sang.

1998

153

et al

Human RhDel is caused by a deletion of 1,013 bp between introns 8 and 9 including exon 9 of RHD gene.

Blood.

1998

2602

2604

154

Sample suitability for the detection of minor leukocyte populations by polymerase chain reaction (PCR) [abstract].

Transfusion.

37(suppl)

1997

107S

155

Incidence of partial D, DIIIa, in Black donors as determined by PCR-RFLP analysis [abstract].

Transfusion.

38(suppl)

1998

63S

156

et al

The genomic organization of the partial D category DVa: the presence of a new partial D associated with the DVa phenotype.

Biochem Biophys Res Commun.

254

1999

786

794

157

PCR-based determination of Rhc and RhE status of fetuses at risk of Rhc and RhE haemolytic disease.

Br J Haematol.

1994

193

195

158

et al

Rh E/e genotyping by allele-specific primer amplification.

Blood.

1995

829

832

159

DNA-based rhesus typing: simultaneous determination of RHC and RHD status using the polymerase chain reaction.

Vox Sang.

1996

164

168

160

et al

Prenatal determination of fetal RhD status by analysis of peripheral blood of rhesus negative mothers.

Lancet.

341

1993

1147

1148

161

et al

Presence of fetal DNA in maternal plasma and serum.

Lancet.

350

1997

485

487

162

et al

Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma.

N Engl J Med.

339

1998

1734

1738

163

Detection of fetal RHD-specific sequences in maternal plasma.

Lancet.

352

1998

1196

164

et al

Prenatal detection of fetal RhD DNA sequences in transcervical samples.

Lancet.

345

1995

318

319

165

Rhesus D typing.

Lancet.

345

1995

661

662

166

Detection of trophoblast cells in transcervical samples collected by lavage or cytobrush.

Obstet Gynecol.

1995

283

288

167

Prenatal detection of rhesus D genotype.

Lancet.

349

1997

540

168

Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood.

Nat Genet.

1996

264

268

169

Male fetal progenitor cells persist in maternal blood for as long as 27 years postpartum.

Proc Natl Acad Sci U S A.

1996

705

708

170

Two siblings with Rhnull disease.

Vox Sang.

1972

182

189

171

et al

Red cell membrane and cation deficiency in Rh null syndrome.

Blood.

1989

1046

1055

172

Hematological aspect of Rh deficiency syndrome: a case report and a review of the literature.

Am J Hematol.

1987

267

275

173

Rhnull human erythrocytes have an abnormal membrane phospholipid organization.

Biochem J.

221

1984

931

934

174

et al

Candidate gene acting as a suppressor of the RH locus in most cases of Rh-deficiency.

Nat Genet.

1996

168

173

175

et al

A novel single missense mutation identified along the RH50 gene in a composite heterozygous Rhnull blood donor of the regulator type.

Blood.

1998

1458

1463

176

Rhnull disease: the amorph type results from a novel double mutation in RhCe gene on D-negative background.

Blood.

1988

664

671

177

et al

Rh-deficiency of the regulator type caused by splicing mutations in the human RH50 gene.

Blood.

1998

2535

2540

178

Associations between human red cell blood group antigens and disease.

Transfus Med Rev.

1990

179

et al

Shift from Rh-positive to Rh-negative phenotype caused by a somatic mutation within the RHD gene in a patient with chronic myelocytic leukaemia.

Br J Haematol.

102

1998

1263

1270

180

Localization of the human Rh blood group gene structure to chromosome region 1p34.3-1p36.1 by in situ hybridization.

Hum Genet.

1991

398

400

181

Molecular basis and expression of the LWa/LWb blood group polymorphism.

Blood.

1995

1590

1594

182

The Diego blood group locus is located on chromosome 17q.

Genomics.

1993

665

666

183

Characterization of the Ss sialoglycoprotein and its antigens in Rhnull erythrocytes.

Blut.

1987

184

Alteration of RH gene structure and expression in human dCCee and DCW- red blood cells: phenotypic homozygosity versus genotypic heterozygosity.

Blood.

1996

2326

2333

185

et al

Molecular analysis of selected Rh variants.

Transfus Clin Biol.

1996

517

519

186

Lack of RHCE-encoded proteins in the D—phenotype may result from homologous recombination between the two RH genes.

Blood.

1996

1518

1520

187

Cheng G-J, Chen Y, Reid ME, Huang C-H. Evans antigen: a new hybrid structure occurring on background of D•• andD—Rh complexes. Vox Sang. In press.

188

Huang C-H, Liu PZ, Cheng JG. Molecular biology and genetics of the Rh blood group system. Semin Hematol. In press.

189

et al

Molecular defects of the RHCE gene in Rh-deficient individuals of the amorph type.

Blood.

1998

639

646

190

et al

Rearrangements of the blood group RhD gene associated with the DVI category phenotype.

Blood.

1994

1129

1135

191

The frequency of RHD protein variants in Caucasians [abstract].

Transfus Clin Biol.

1996

10S

192

et al

Molecular basis of the D variant phenotypes DNU and DII allows localization of critical amino acids required for expression of Rh D epitopes epD3, 4 and 9 to the sixth external domain of the Rh D protein.

Br J Haematol.

1997

366

371

193

Leu110Pro substitution in the RhD polypeptide is responsible for the DVII category blood group phenotype.

Am J Hematol.

1995

194

et al

Transcript analysis of D category phenotypes predicts hybrid Rh D-CE-D proteins associated with alteration of D epitopes.

Blood.

1995

2937

2944

195

Characterization of D category IV type IV, DFW, and DNB [abstract].

Transfusion.

38(suppl)

1998

63S

196

et al

The serological profile and molecular basis of a new partial D phenotype, DHR.

Vox Sang.

1997

252

256

197

Human DIIIa erythrocytes: RhD protein is associated with multiple dispersed amino acid variations.

Am J Hematol.

1997

139

145

198

et al

Characterization of the hybrid RHD gene leading to the partial D category IIIc phenotype.

Transfusion.

1996

567

574

199

et al

Molecular analysis of Rh transcripts and polypeptides from individuals expressing the DVI variant phenotype: an RHD gene deletion event does not generate all DVIccEe phenotypes.

Blood.

1997

1779

1786

200

Human DVI category erythrocytes: correlation of the phenotype with a novel hybrid RhD-CE-D gene but not an internally deleted RhD gene.

Blood.

1997

1834

1835

201

Molecular characterization of qualitative Rh variants.

Biotest Bull.

1997

439

449

202

et al

The genetic basis of a new partial D antigen: DDBT.

Br J Haematol.

1996

720

727

203

Huang C-H, Chen Y, Reid ME, Okubo Y. Evidence for a separate genetic origin of the partial D phenotype DBT in a Japanese family. Transfusion. In press.

204

et al

ARRO-I: a new partial D phenotype involving exon 4 and 5 [abstact].

Vox Sang.

74(suppl 1)

1998

1331

205

A new variant of Rh(D) antigen: revealed by reactions of anti-ep12 monoclonal antibodies and lacking exon 5 D-specific reaction of exon-scanning RHD/CE PCR-SSP [abstract].

Vox Sang.

74(suppl 1)

1998

1332

206

Involvement of Gly96 in the formation of the Rh26 epitope.

Transfusion.

1997

1123

1130

207

The R0HarRh:33 phenotype results from substitution of exon 5 of the RHCE gene by the corresponding exon of the RHD gene.

Br J Haematol.

1996

751

757

208

et al

Molecular analysis of blood group Rh transcripts from a rGr variant.

Br J Haematol.

1996

472

474

209

Rh mod syndrome: a family study of the translation-initiator mutation in the Rh50 glycoprotein gene.

Am J Hum Genet.

1999

108

117

210

Huang C-H, Cheng G, Liu Z, et al. Molecular basis for Rhnull syndrome: identification of three new missense mutations in the Rh50 glycoprotein gene. Am J Hematol. In press.

211

Sequence analysis of the spacer region between the RHD and RHCE genes.

Biochem Biophys Res Commun.

263

1999

378

383

2000

Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.

Comment not saved. Please try again.

What is the clinical significance of Rh blood group?

Why Is Rh Factor Important? The Rh factor is one of the proteins on RBCs used to indicate whether the blood of two different people is compatible when mixed – such as blood of a mother and her baby at birth. It is routine and important that the Rh factor for a mother and unborn child be determined during pregnancy.

Why is Rh antibodies clinically significant?

Clinical significance of Rh antibodies The Rh antigens are highly immunogenic, and most of the Rh antibodies should be considered as potential causes of hemolytic transfusion reactions and HDN.

What are the ideal reaction conditions for Rh antibodies?

Reactivity of Rh antibodies is enhanced by enzyme treatment of the test RBCs, and most react optimally at 37°C.

What is the Rh disease?

Rhesus disease is a condition where antibodies in a pregnant woman's blood destroy her baby's blood cells. It's also known as haemolytic disease of the foetus and newborn (HDFN). Rhesus disease doesn't harm the mother, but it can cause the baby to become anaemic and develop newborn jaundice.